Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Juliet Hockenhull"'
Autor:
Amanda Nicholson, James Mahon, Angela Boland, Sophie Beale, Kerry Dwan, Nigel Fleeman, Juliet Hockenhull, Yenal Dundar
Publikováno v:
Health Technology Assessment, Vol 19, Iss 87 (2015)
Background: There is no single definitive test to identify prostate cancer in men. Biopsies are commonly used to obtain samples of prostate tissue for histopathological examination. However, this approach frequently misses cases of cancer, meaning th
Externí odkaz:
https://doaj.org/article/286d54a9a44b401cab0c4ec1b667c174
Autor:
Janette Greenhalgh, Adrian Bagust, Angela Boland, Kerry Dwan, Sophie Beale, Juliet Hockenhull, Christine Proudlove, Yenal Dundar, Marty Richardson, Rumona Dickson, Anna Mullard, Ernie Marshall
Publikováno v:
Health Technology Assessment, Vol 19, Iss 47 (2015)
Background: Lung cancer is the second most diagnosed cancer in the UK. Over 70% of lung cancers are non-small cell lung cancers (NSCLCs). Patients with stage III or IV NSCLC may be offered treatment to improve survival, disease control and quality of
Externí odkaz:
https://doaj.org/article/c70b03fecff94bb1aea0b6e525844673
Autor:
Juliet Hockenhull, Yenal Dundar, James Mahon, Angela Boland, Sophie Beale, Kerry Dwan, Amanda Nicholson, Nigel Fleeman
Publikováno v:
Health Technology Assessment, Vol 19, Iss 87 (2015)
BackgroundThere is no single definitive test to identify prostate cancer in men. Biopsies are commonly used to obtain samples of prostate tissue for histopathological examination. However, this approach frequently misses cases of cancer, meaning that
Autor:
Janette Greenhalgh, James Oyee, Chris Proudlove, Susan O’Reilly, Nicola Trevor, Angela Boland, Juliet Hockenhull, Sophie Beale, Adrian Bagust, Yenal Dundar
Publikováno v:
PharmacoEconomics. 33:137-148
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of eribulin (Eisai Ltd) to submit evidence for the clinical and cost effectiveness of eribulin as treatment for patients with locally advanced or metastatic breast
Autor:
C Martin Saborido, Adrian Bagust, V. S. Ramani, J Oyee, Michaela Blundell, Juliet Hockenhull, Angela Boland, Yenal Dundar, Rumona Dickson, Hilary Davis
Publikováno v:
PharmacoEconomics Italian Research Articles. 15:35-44
The UK National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of erlotinib (Roche) to submit evidence for the clinical and cost effectiveness of erlotinib as monotherapy for the maintenance treatment of patients with no
Autor:
Adrian Bagust, Patrick Chu, Juliet Hockenhull, James Oyee, Chris Proudlove, Janette Greenhalgh, Yenal Dundar, Angela Boland, Michaela Blundell, Sophie Beale
Publikováno v:
PharmacoEconomics. 31:403-413
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of rituximab (RTX) [Roche] to submit evidence for the clinical and cost effectiveness of RTX as first-line maintenance treatment for patients with follicular no
Publikováno v:
The Cochrane database of systematic reviews. (10)
Publikováno v:
Cochrane Database of Systematic Reviews.
Autor:
Carlos Martin Saborido, Angela Boland, James Oyee, Adrian Bagust, Yenal Dundar, Rumona Dickson, Michaela Blundell, Juliet Hockenhull, Vidhya Sagar Ramani, H Davis
Publikováno v:
PharmacoEconomics. 29:1051-1062
The UK National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of erlotinib (Roche) to submit evidence for the clinical and cost effectiveness of erlotinib as monotherapy for the maintenance treatment of patients with no
Autor:
Rumona Dickson, Tom Walley, Juliet Hockenhull, Kerry Dwan, Godfrey W. Smith, Carrol Gamble, Angela Boland
Publikováno v:
Critical Care Medicine. 37:702-712
To assess the clinical effectiveness of central venous catheters (CVCs) treated with anti-infective agents (AI-CVCs) in preventing catheter-related bloodstream infections (CRBSI).MEDLINE (OVID), EMBASE, SCI//Web of Science, SCI/ISI Proceedings, and t